Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Core Viewpoint - Shattuck Labs, Inc. has granted inducement equity awards to a newly-hired non-executive officer as part of its strategy to attract talent in the biotechnology sector focused on inflammatory and immune-mediated diseases [1][2]. Group 1: Inducement Equity Awards - The inducement awards consist of non-qualified stock options to purchase 206,000 shares of common stock at an exercise price of $3.23 per share [2]. - The stock options have a maximum term of 10 years, with 25% vesting on November 17, 2026, and the remainder vesting in equal monthly installments over the following 36 months [2]. - These stock options were granted as a material inducement for employment and were approved by the independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4) [2]. Group 2: Company Overview - Shattuck Labs, Inc. is a clinical-stage biotechnology company specializing in developing treatments for inflammatory and immune-mediated diseases [3]. - The company is working on a potentially first-in-class antibody for inflammatory bowel disease (IBD) and other related conditions [3]. - Shattuck's lead program, SL-325, is a DR3 antagonist antibody aimed at achieving a more complete blockade of the DR3/TL1A pathway [3].